BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

915 related articles for article (PubMed ID: 28436755)

  • 1. Modes of Action for Mucosal Vaccine Adjuvants.
    Aoshi T
    Viral Immunol; 2017; 30(6):463-470. PubMed ID: 28436755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
    Lawson LB; Norton EB; Clements JD
    Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.
    Wang X; Meng D
    Protein Cell; 2015 Mar; 6(3):170-84. PubMed ID: 25503634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights in mucosal vaccine development.
    Pavot V; Rochereau N; Genin C; Verrier B; Paul S
    Vaccine; 2012 Jan; 30(2):142-54. PubMed ID: 22085556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines.
    Kataoka K; Fujihashi K
    Expert Rev Vaccines; 2009 Sep; 8(9):1183-93. PubMed ID: 19722892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous and Exogenous Natural Adjuvants for Vaccine Development.
    Bolhassani A; Talebi S; Anvar A
    Mini Rev Med Chem; 2017; 17(15):1442-1456. PubMed ID: 28245781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal Vaccine Development Based on Liposome Technology.
    Bernasconi V; Norling K; Bally M; Höök F; Lycke NY
    J Immunol Res; 2016; 2016():5482087. PubMed ID: 28127567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
    Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA
    Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flagellin as a vaccine adjuvant.
    Cui B; Liu X; Fang Y; Zhou P; Zhang Y; Wang Y
    Expert Rev Vaccines; 2018 Apr; 17(4):335-349. PubMed ID: 29580106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.
    Henderson A; Propst K; Kedl R; Dow S
    Vaccine; 2011 Jul; 29(32):5304-12. PubMed ID: 21600950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y; Kiyono H
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
    Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
    APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
    Vajdy M; Srivastava I; Polo J; Donnelly J; O'Hagan D; Singh M
    Immunol Cell Biol; 2004 Dec; 82(6):617-27. PubMed ID: 15550120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
    Leroux-Roels G
    Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan-based mucosal adjuvants: Sunrise on the ocean.
    Xia Y; Fan Q; Hao D; Wu J; Ma G; Su Z
    Vaccine; 2015 Nov; 33(44):5997-6010. PubMed ID: 26271831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
    Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of CpG DNA as a mucosal vaccine adjuvant.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Curr Opin Investig Drugs; 2001 Jan; 2(1):35-9. PubMed ID: 11527008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
    Ho NI; Huis In 't Veld LGM; Raaijmakers TK; Adema GJ
    Front Immunol; 2018; 9():2874. PubMed ID: 30619259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.